Other languages C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
6.17 ^USD	-1.12%		-8.18%	+9.20%

04-08	C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	CI
03-18	C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	04-08
C4 Therapeutics Collaborating With Germany's Merck KGaA to Advance Research on Targeted Therapies for Cancer	03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA Against Critical Oncogenic Proteins	03-04
C4 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22
C4 Therapeutics Shares Jump After JPMorgan Upgrade	01-29
Top Midday Gainers	12-13
Sector Update: Health Care Stocks Flat Premarket Wednesday	12-13
C4 Therapeutics Flags 'Promising' Early Data in Trial of Multiple Myeloma, Non-Hodgkin's Lymphomas Treatment	12-13
Sector Update: Health Care Stocks Advance Late Afternoon	12-12
C4 Therapeutics, Inc. Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma	12-12
Sector Update: Health Care	12-12
Top Midday Gainers	12-12
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12-12
Investors Await Inflation Data, Look to Last Fed Meeting of Year as US Futures Rise Slightly in Tuesday's Premarket	12-12
Top Premarket Gainers	12-12
C4 Therapeutics, Inc. Appoints Owen Hughes to Its Board of Directors	11-20
C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01
Top Premarket Decliners	23-10-12
C4 Therapeutics, Inc. Announces Upcoming Data Presentations for CFT8634 and CFT7455	23-10-11
C4 Therapeutics, Inc. Announces Executive Changes, Effective as of September 18, 2023	23-09-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Other languages

Filters